Particle.news

Trump Demands Some Childhood Vaccines Be Split Into Five Doses

Public-health experts say the proposal lacks scientific support.

Administrator for the Centers for Medicare and Medicaid Services Dr Mehmet Oz smiles as US President Donald J. Trump interacts with U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. during an announcement on healthcare in the Oval Office at the White House, in Washington, D.C., US, September 18, 2026. REUTERS/Evan Vucci
Administrator for the Centers for Medicare and Medicaid Services Dr Mehmet Oz speaks next to US Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. and  US President Donald J. Trump during an announcement on healthcare in the Oval Office at the White House, in Washington, D.C., US, September 18, 2026. REUTERS/Evan Vucci
US Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. and Administrator for the Centers for Medicare and Medicaid Services Dr Mehmet Oz listen to US President Donald J. Trump as he makes an announcement on healthcare in the Oval Office at the White House in Washington, D.C., US, September 18, 2026. REUTERS/Evan Vucci
US President Donald J. Trump makes an announcement on healthcare in the Oval Office at the White House in Washington, D.C., US, September 18, 2026. REUTERS/Evan Vucci

Overview

  • President Trump said on Friday he will press drugmakers to break certain routine childhood vaccines into five smaller, 20% doses given about six months apart and claimed the change would cut autism rates.
  • He did not name specific vaccines and offered no scientific evidence for a link between vaccines and autism, following an August executive order that already sought to cut the federal childhood vaccine list to 11 shots and to separate the MMR vaccine.
  • Vaccine scientists including Dr. Paul Offit say reducing dose size and spacing shots would likely make vaccines ineffective because dosing and schedules are set by trials to ensure protective immune responses.
  • Changing combination vaccines or creating single-antigen or lower-dose versions would require new clinical trials, FDA approvals and manufacturing changes that could take years, and manufacturers have signaled reluctance.
  • The move has raised legal and political fights after courts blocked earlier federal schedule changes and some states resisted White House direction, and public-health officials warn the messaging could increase hesitancy and risk more outbreaks.